Another stock that insiders are snapping up here is Cryolife ( CRY), which preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. Insiders are buying this stock into some modest weakness since shares are off by just 3.9% so far in 2012. Cryolife has a market cap of $127 million and an enterprise value of $108 million. This stock trades at a reasonable valuation, with a trailing price-to-earnings of 19.29 and a forward price-to-earnings of 13.56. Its estimated growth rate for this year is -62.9%, and for next year it's pegged at 161.50%. This is cash-rich company, since the total cash position on its balance sheet is $21.15 million and its total debt is zero. A director just bought 25,000 shares, or about $119,000 worth of stock, at $4.79 per share. From a technical perspective, CRY is currently trading below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending for the last four months, with shares sliding lower from a high of $6.02 to a recent low of $4.19 a share. During that move, shares of CRY have consistently made lower highs and lower lows which is bearish technical price action. >>Hot Biotech Stocks Traded by Hedge Funds If you're in the bull camp on CRY, then I would only look for long-biased trades once it triggers a move back above its 200-day at $4.95, and then its 50-day at $4.99 a share with high-volume. Look for volume on that move that's close to or above its three-month average action of 85,523 shares. I would only be interested in CRY if it can sustain a trend above both of those key moving averages with strong upside volume flows. On the flipside, I would avoid CRY or look for short-biased trades if it fails to trigger that move, and then drops below some near-term support at $4.40 to $4 a share with heavy volume. A move below $4 would be very bearish for CRY since it would mean the stock has entered new 52-week-low territory.